Next Article in Journal
Early Fixation of Cobalt-Chromium Based Alloy Surgical Implants to Bone Using a Tissue-engineering Approach
Next Article in Special Issue
Characterization of ARF-BP1/HUWE1 Interactions with CTCF, MYC, ARF and p53 in MYC-Driven B Cell Neoplasms
Previous Article in Journal
Evaluation of Antioxidant and Antiproliferative Properties of Three Actinidia (Actinidia kolomikta, Actinidia arguta, Actinidia chinensis) Extracts in Vitro
Previous Article in Special Issue
Evaluation of the Adenocarcinoma-Associated Gene AGR2 and the Intestinal Stem Cell Marker LGR5 as Biomarkers in Colorectal Cancer
Open AccessArticle

Evaluation of HER2 Gene Amplification in Breast Cancer Using Nuclei Microarray in Situ Hybridization

by 1,†, 2,†, 1 and 1,*
1
Department of General Surgery, General Hospital of Shenyang Military Area Command, No. 83, Wenhua Road, Shenhe District, Shenyang 110840, China
2
Division of Nephrology, Guangdong Provincial Institute of Nephrology, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong 510515, China
*
Author to whom correspondence should be addressed.
These authors contributed equally to this work.
Int. J. Mol. Sci. 2012, 13(5), 5519-5527; https://doi.org/10.3390/ijms13055519
Received: 10 April 2012 / Revised: 26 April 2012 / Accepted: 27 April 2012 / Published: 8 May 2012
(This article belongs to the Special Issue Advances in Molecular Oncology (special issue))
Fluorescence in situ hybridization (FISH) assay is considered the “gold standard” in evaluating HER2/neu (HER2) gene status. However, FISH detection is costly and time consuming. Thus, we established nuclei microarray with extracted intact nuclei from paraffin embedded breast cancer tissues for FISH detection. The nuclei microarray FISH (NMFISH) technology serves as a useful platform for analyzing HER2 gene/chromosome 17 centromere ratio. We examined HER2 gene status in 152 cases of invasive ductal carcinomas of the breast that were resected surgically with FISH and NMFISH. HER2 gene amplification status was classified according to the guidelines of the American Society of Clinical Oncology and College of American Pathologists (ASCO/CAP). Comparison of the cut-off values for HER2/chromosome 17 centromere copy number ratio obtained by NMFISH and FISH showed that there was almost perfect agreement between the two methods (κ coefficient 0.920). The results of the two methods were almost consistent for the evaluation of HER2 gene counts. The present study proved that NMFISH is comparable with FISH for evaluating HER2 gene status. The use of nuclei microarray technology is highly efficient, time and reagent conserving and inexpensive. View Full-Text
Keywords: breast cancer; microarray; nuclei microarray; fluorescence in situ hybridization (FISH); HER2 gene breast cancer; microarray; nuclei microarray; fluorescence in situ hybridization (FISH); HER2 gene
Show Figures

MDPI and ACS Style

Jiang, H.; Bai, X.; Zhang, C.; Zhang, X. Evaluation of HER2 Gene Amplification in Breast Cancer Using Nuclei Microarray in Situ Hybridization. Int. J. Mol. Sci. 2012, 13, 5519-5527. https://doi.org/10.3390/ijms13055519

AMA Style

Jiang H, Bai X, Zhang C, Zhang X. Evaluation of HER2 Gene Amplification in Breast Cancer Using Nuclei Microarray in Situ Hybridization. International Journal of Molecular Sciences. 2012; 13(5):5519-5527. https://doi.org/10.3390/ijms13055519

Chicago/Turabian Style

Jiang, Huiyong; Bai, Xiaoyan; Zhang, Cheng; Zhang, Xuefeng. 2012. "Evaluation of HER2 Gene Amplification in Breast Cancer Using Nuclei Microarray in Situ Hybridization" Int. J. Mol. Sci. 13, no. 5: 5519-5527. https://doi.org/10.3390/ijms13055519

Find Other Styles

Article Access Map by Country/Region

1
Only visits after 24 November 2015 are recorded.
Search more from Scilit
 
Search
Back to TopTop